CY1123499T1 - Αντισωματα τα οποια δεσμευονται ειδικως στον tl1a - Google Patents
Αντισωματα τα οποια δεσμευονται ειδικως στον tl1aInfo
- Publication number
- CY1123499T1 CY1123499T1 CY20201100767T CY201100767T CY1123499T1 CY 1123499 T1 CY1123499 T1 CY 1123499T1 CY 20201100767 T CY20201100767 T CY 20201100767T CY 201100767 T CY201100767 T CY 201100767T CY 1123499 T1 CY1123499 T1 CY 1123499T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- tl1a
- disease
- cystic fibrosis
- specifically bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Παρέχονται εκφραζόμενα με ανασυνδυασμό αντισώματα παραλλαγής, τα οποία έχουν ενισχυμένη συγγένεια για τον TL1A και ενισχυμένη ισχύ σχετική με το γονικό αντίσωμα από το οποίο προήλθαν. Τα αντισώματα αναστέλλουν την αλληλεπίδραση μεταξύ του TL1A και του υποδοχέα θανάτου 3 (DR3). Τα αντισώματα ή μια σύνθεση αυτών, δύνανται να χρησιμοποιηθούν για τη θεραπευτική αντιμετώπιση ενός ή περισσοτέρων εκ των άσθματος, COPD, πνευμονικής ίνωσης, κυστικής ίνωσης, φλεγμονώδους νόσου του εντέρου, γαστρεντερικής νόσου σχετιζόμενης με κυστική ίνωση, νόσου του Crohn, κολίτιδας, ελκώδους κολίτιδας, συνδρόμου ευερέθιστου εντέρου, ηωσινοφιλικής οισοφαγίτιδας, ατοπικής δερματίτιδας, εκζέματος, σκληροδερμίας, αρθρίτιδας ή ρευματοειδούς αρθρίτιδας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220442P | 2015-09-18 | 2015-09-18 | |
PCT/US2016/052040 WO2017049024A1 (en) | 2015-09-18 | 2016-09-16 | Antibodies that specifically bind to tl1a |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123499T1 true CY1123499T1 (el) | 2022-03-24 |
Family
ID=57043002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100767T CY1123499T1 (el) | 2015-09-18 | 2020-08-17 | Αντισωματα τα οποια δεσμευονται ειδικως στον tl1a |
Country Status (33)
Country | Link |
---|---|
US (3) | US10138296B2 (el) |
EP (2) | EP3350223B1 (el) |
JP (2) | JP7013366B2 (el) |
KR (1) | KR101998535B1 (el) |
CN (1) | CN108137693B (el) |
AR (1) | AR106055A1 (el) |
AU (2) | AU2016323460B2 (el) |
BR (2) | BR112018005407A8 (el) |
CA (1) | CA2997015A1 (el) |
CL (1) | CL2018000711A1 (el) |
CO (1) | CO2018003736A2 (el) |
CY (1) | CY1123499T1 (el) |
DK (1) | DK3350223T3 (el) |
EA (1) | EA201890756A1 (el) |
ES (1) | ES2810751T3 (el) |
HK (2) | HK1251002A1 (el) |
HR (1) | HRP20201323T1 (el) |
HU (1) | HUE051496T2 (el) |
IL (1) | IL257761B2 (el) |
LT (1) | LT3350223T (el) |
MA (2) | MA42825B1 (el) |
MD (1) | MD3350223T2 (el) |
MX (1) | MX2018003185A (el) |
PE (1) | PE20181080A1 (el) |
PH (1) | PH12018500580A1 (el) |
PL (1) | PL3350223T3 (el) |
PT (1) | PT3350223T (el) |
RS (1) | RS60703B1 (el) |
SI (1) | SI3350223T1 (el) |
TW (1) | TWI703158B (el) |
UA (1) | UA125284C2 (el) |
WO (1) | WO2017049024A1 (el) |
ZA (1) | ZA201801427B (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
CN104114577A (zh) | 2011-09-30 | 2014-10-22 | 特瓦制药澳大利亚私人有限公司 | 针对TL1a的抗体及其用途 |
CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
IL259752B (en) * | 2015-12-04 | 2022-07-01 | Univ Iowa Res Found | Device, systems and methods for prediction, screening and monitoring of encephalopathy / delirium |
EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
CN110121509B (zh) | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
AU2018259856A1 (en) * | 2017-04-28 | 2019-11-14 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
US20210070871A1 (en) | 2018-04-25 | 2021-03-11 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
WO2024026386A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1667730B1 (en) | 2003-08-20 | 2013-06-26 | University of Miami | Compositions and methods for treating inflammatory lung disease |
AU2005227322A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
US20090269345A1 (en) | 2005-12-23 | 2009-10-29 | Rong Fan | CLN248 Antibody Compositions and Methods of Use |
US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
JP5745854B2 (ja) | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Tl1aに対するヒト化抗体 |
US20120073585A1 (en) | 2009-04-08 | 2012-03-29 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
EP2519260A2 (en) | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
KR20140104344A (ko) | 2011-05-20 | 2014-08-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 | T 세포 매개성 질병의 병증을 개선하기 위한 tl1a-dr3의 상호작용의 차단 및 그것의 항체 |
CN104114577A (zh) * | 2011-09-30 | 2014-10-22 | 特瓦制药澳大利亚私人有限公司 | 针对TL1a的抗体及其用途 |
TR201815254T4 (tr) | 2013-01-02 | 2018-11-21 | Glenmark Pharmaceuticals Sa | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari |
CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP2981286A4 (en) * | 2013-04-05 | 2016-08-24 | Hoffmann La Roche | ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF |
EP2996717A4 (en) | 2013-05-17 | 2016-11-23 | Cedars Sinai Medical Center | DISTINCT EFFECTS OF IFN GAMMA AND IL-17 ON TL1A-MODIFIED INFLAMMATION AND FIBROSIS |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
WO2015035261A1 (en) | 2013-09-06 | 2015-03-12 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
BR112017022117A2 (pt) | 2015-04-15 | 2018-07-10 | Biosearch Technologies, Inc. | “sondas duplas supressoras” |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
-
2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 BR BR112018005407A patent/BR112018005407A8/pt active Search and Examination
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/en active Application Filing
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/en active Active
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt unknown
- 2016-09-16 CA CA2997015A patent/CA2997015A1/en active Pending
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/en active Pending
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active IP Right Grant
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
-
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-03-16 PH PH12018500580A patent/PH12018500580A1/en unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-08-15 HK HK18110481.5A patent/HK1251002A1/zh unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
- 2018-11-30 HK HK18115365.5A patent/HK1256300A1/zh unknown
-
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
- 2020-08-25 HR HRP20201323TT patent/HRP20201323T1/hr unknown
-
2021
- 2021-11-30 US US17/538,530 patent/US20220185902A1/en active Pending
-
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
-
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123499T1 (el) | Αντισωματα τα οποια δεσμευονται ειδικως στον tl1a | |
PH12018500657A1 (en) | Optimized variants of anti-vegf antibodies | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
MX2017012429A (es) | Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3). | |
MX2020001272A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
EA201890565A1 (ru) | Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз | |
EA201791562A1 (ru) | Антигены цитомегаловируса и их применения | |
BR112016026299A2 (pt) | molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão | |
BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
WO2018035084A8 (en) | Monovalent asymmetric tandem fab bispecific antibodies | |
MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
EA201790441A1 (ru) | Антитела к il-25 и их применения | |
CL2016001028A1 (es) | Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh. | |
DK3265487T3 (da) | Modificeret igg-antistoffer, der binder transformerende vækstfaktor-beta1 med høj affinitet, aviditet og specificitet | |
WO2014172448A3 (en) | Antibodies directed against activin receptor type ii (actrii) | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
MY197821A (en) | Anti-il-22r antibodies | |
WO2015116569A3 (en) | Antibodies directed against discoidin domain receptor family, member 1 (ddr1) | |
WO2015153949A3 (en) | Compositions and methods for identifying ehrlichia species | |
EA201890741A1 (ru) | Биспецифические антитела против cgrp/il-23 и их применения | |
MX2018009218A (es) | Anticuerpos de cgrp y sus usos. | |
WO2017106609A3 (en) | Pdgfr beta antibody | |
EA201892124A1 (ru) | Днк-конструкции антител и способы их применения |